Kymera Therapeutics to Announce KT-579 Phase 1 Trial Results October 29
Kymera Therapeutics said it will announce results from the KT-579 Phase 1 healthy volunteer trial on October 29, 2026.
Related stories
Nasdaq Falls as Alphabet Faces Record Loss Amid AI Spending Woes
U.S. stocks are lower, with the Dow down 0.35%. Alphabet is set for a record loss amid concerns over AI spending.
M impact | EQUITY | Oct 29, 2026, 04:44 PM UTC
High Quality Food reports Q3 2026 revenue of €4.6 million
M impact | EQUITY | Oct 29, 2026, 04:44 PM UTC
CPV Secures $825 Million Financing for Two U.S. Power Plants
OPC Energy's U.S. subsidiary CPV secured $825 million in financing for the Shore and Maryland power plants. The structure consolidates existing project-level debt under a single fa
M impact | EQUITY | Oct 29, 2026, 04:43 PM UTC
X-FAB Expects Q4 Revenue of $205-215 Million
X-FAB expects fourth-quarter revenue within a range of $205-215 million.
M impact | EQUITY | Oct 29, 2026, 04:43 PM UTC
Pilgrim’s Pride Q3 Profit Falls
M impact | EQUITY | Oct 29, 2026, 04:42 PM UTC
NX Filtration Launches Private Share Placement of Up to EUR 20 Million
NX Filtration launched a private share placement of up to EUR 20 million.
M impact | EQUITY | Oct 29, 2026, 04:41 PM UTC